Vivos Therapeutics, Inc.VVOSEarnings & Financial Report
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
VVOS Q3 2025 Key Financial Metrics
Revenue
$6.8M
Gross Profit
$3.9M
Operating Profit
$-4.7M
Net Profit
$-5.4M
Gross Margin
58.0%
Operating Margin
-69.8%
Net Margin
-79.6%
YoY Growth
75.7%
EPS
$-0.49
Financial Flow
Vivos Therapeutics, Inc. Q3 2025 Financial Summary
Vivos Therapeutics, Inc. reported revenue of $6.8M for Q3 2025, with a net profit of $-5.4M (-79.6% margin). Cost of goods sold was $2.8M, operating expenses totaled $8.7M.
Key Financial Metrics
| Total Revenue | $6.8M |
|---|---|
| Net Profit | $-5.4M |
| Gross Margin | 58.0% |
| Operating Margin | -69.8% |
| Report Period | Q3 2025 |
Vivos Therapeutics, Inc. Annual Revenue by Year
Vivos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $15.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $15.0M |
| 2023 | $13.8M |
| 2022 | $16.0M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $3.4M | $4.1M | $3.9M | $3.7M | $3.0M | $3.8M | $6.8M |
| YoY Growth | -21.4% | -11.4% | 19.4% | 16.9% | 13.9% | -11.8% | -5.8% | 75.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.7M | $11.8M | $15.8M | $15.3M | $15.3M | $11.3M | $26.0M | $25.6M |
| Liabilities | $10.3M | $11.2M | $9.5M | $7.7M | $7.3M | $6.9M | $21.4M | $23.1M |
| Equity | $411000 | $582000 | $6.3M | $7.7M | $8.0M | $4.4M | $4.6M | $2.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.7M | $-2.5M | $-3.0M | $-4.2M | $-2.9M | $-3.8M | $-3.5M | $-4.2M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M